Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Virtual Plenary: December 2021

Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study
ESMO-Virtual-Plenary-December-2021-1000x250

Airs on 16 December 2021 at 19:30 CET

Start date
16 Dec 2021
End date
17 Dec 2021
Live on
16 Dec 2021

The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.

The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study

Programme

Thursday, 16 December 2021

19:30-20:30 CET

Welcome and introduction, Scientific background and context

Andrés Cervantes, Hospital Clinico Universitario de Valencia, Valencia, Spain

Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study

Thierry André, Hôpital Saint-Antoine, Paris, France

Critical analysis and perspectives

Demetris Papamichael, Bank of Cyprus Oncology Centre, Nicosia, Cyprus

Discussion and Q&A (i)

Faculty and online audience

Friday, 17 December 2021

13:00-14:10 CET / 14:00-15:10 EET / 17:30-18:40 IST / 20:00-21:10 CST / 21:00-22:10 JST

Virtual Plenary Expert Insights: Webcast of 16 December presentations, Discussion and Q&A (ii)

Faculty and online audience

Chair: Takayuki Yoshino, National Cancer Center Hospital East, Kashiwa, Japan

Thierry André, Hôpital Saint-Antoine, Paris, France

Demetris Papamichael, Bank of Cyprus Oncology Centre, Nicosia, Cyprus

Miriam Koopman, UMC - University Medical Center Utrecht, Utrecht, Netherlands 

Smruti Koppikar, Bombay Hospital and Medical Research Center, Mumbai, India

Plus one panellist to be announced

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings